These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 9057632)
41. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. Watts MJ; Sullivan AM; Leverett D; Peniket AJ; Perry AR; Williams CD; Devereux S; Goldstone AH; Linch DC J Clin Oncol; 1998 Apr; 16(4):1554-60. PubMed ID: 9552065 [TBL] [Abstract][Full Text] [Related]
42. The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed. D'Hondt L; Emmons RV; André M; Guillaume T; Feyens AM; Canon JL; Humblet Y; Longueville J; Symann M Leuk Lymphoma; 1999 Jun; 34(1-2):105-9. PubMed ID: 10350337 [TBL] [Abstract][Full Text] [Related]
43. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838 [TBL] [Abstract][Full Text] [Related]
44. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. Kawano Y; Takaue Y; Mimaya J; Horikoshi Y; Watanabe T; Abe T; Shimizu Y; Matsushita T; Kikuta A; Watanabe A; Iwai A; Ito E; Endo M; Kodani N; Ohta S; Gushi K; Azuma H; Etoh T; Okamoto Y; Amano K; Hattori H; Eguchi H; Kuroda Y Blood; 1998 Dec; 92(11):4040-6. PubMed ID: 9834207 [TBL] [Abstract][Full Text] [Related]
45. Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY. Weaver CH; Schwartzberg LS; Zhen B; Franco C; Moore M; Smith R; White L; Van Amburg A; Hazelton B; Buckner CD Bone Marrow Transplant; 1999 Mar; 23(5):421-5. PubMed ID: 10100554 [TBL] [Abstract][Full Text] [Related]
46. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Lemoli RM; Fortuna A; Motta MR; Rizzi S; Giudice V; Nannetti A; Martinelli G; Cavo M; Amabile M; Mangianti S; Fogli M; Conte R; Tura S Blood; 1996 Feb; 87(4):1625-34. PubMed ID: 8608257 [TBL] [Abstract][Full Text] [Related]
47. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients. Goldman SC; Bracho F; Davenport V; Slack R; Areman E; Shen V; Lenarsky C; Weinthal J; Hughes R; Cairo MS J Pediatr Hematol Oncol; 2001; 23(5):300-5. PubMed ID: 11464987 [TBL] [Abstract][Full Text] [Related]
48. Peripheral blood stem cell (PBSC) mobilization and transplantation (PSCT) in patients with malignant lymphomas and solid tumors. Richel DJ; Van der Wall E; Slaper J; Van der Schoot E; Rodenhuis S Int J Artif Organs; 1993 Dec; 16 Suppl 5():71-5. PubMed ID: 7516919 [TBL] [Abstract][Full Text] [Related]
49. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg). Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796 [TBL] [Abstract][Full Text] [Related]
50. Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer. Laport GG; Valone FH; Zimmerman TM; Grinblatt DL; Van Vlasselaer P; Still BJ; Williams SF Cytotherapy; 2000; 2(3):179-85. PubMed ID: 12042040 [TBL] [Abstract][Full Text] [Related]
51. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Lane TA; Law P; Maruyama M; Young D; Burgess J; Mullen M; Mealiffe M; Terstappen LW; Hardwick A; Moubayed M Blood; 1995 Jan; 85(1):275-82. PubMed ID: 7528570 [TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736 [TBL] [Abstract][Full Text] [Related]
53. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells. Meisenberg B; Brehm T; Schmeckel A; Miller W; McMillan R Transfusion; 1998 Feb; 38(2):209-15. PubMed ID: 9531956 [TBL] [Abstract][Full Text] [Related]
54. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
56. Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involvement. Viret F; Blaise D; Bouabdallah R; Stoppa AM; Novakovitch G; Faucher C; Vey N; Camerlo J; Oziel-Taieb S; Ladaique P; Gastaut JA; Maraninchi D; Chabannon C Hematol Cell Ther; 1999 Feb; 41(1):5-11. PubMed ID: 10193640 [TBL] [Abstract][Full Text] [Related]
57. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor. Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727 [TBL] [Abstract][Full Text] [Related]
58. Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity. Li B; Yang JL; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang S; Zhang CG Cytotherapy; 2009; 11(3):362-71. PubMed ID: 19037766 [TBL] [Abstract][Full Text] [Related]
59. Peripheral blood stem cells: in vivo biology and therapeutic potential. Scheding S; Brugger W; Mertelsmann R; Kanz L Stem Cells; 1994; 12 Suppl 1():203-10; discussion 211. PubMed ID: 7535146 [TBL] [Abstract][Full Text] [Related]
60. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group. Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]